EBR Systems launches AU$150M raise to fund US WISE rollout
What's the deal? Australian medtech company EBR Systems has launched a fully underwritten $150 million capital raise to fund the US commercial expansion of WISE, its wireless cardiac pacing device for heart failure patients. The raise consists of a $64.4 million institutional placement and an $85.6 million accelerated entitlement offer, priced at 38 cents per share — a 19.1% discount to its last closing price.
Funds advised by Brandon Capital PartnersDealroom has a profile for this one. Try Dealroom → have committed up to $46.65 million. The proceeds will go toward sales and marketing, manufacturing scale-up, R&D, and clinical programmes, with the goal of reaching cashflow breakeven.
Post-raise, EBR expects to hold pro-forma cash of around US$133.4 million.
Why now? The raise comes on the heels of several pivotal milestones. The US Food and Drug Administration cleared WISE as a breakthrough device in April 2025, and EBR has already begun a staged US rollout.
The Centers for Medicare & Medicaid Services (CMS) has initiated a National Coverage Determination (NCD) process for WISE — a fast-tracked pathway that could deliver national Medicare coverage by early 2027, well ahead of the typical three-to-five-year timeline. The CMS also included WISE in its New Technology Add-on Payment programme, covering both inpatient and outpatient procedures and enabling a selling price of US$63,300 per device.
EBR has already signed more than 39 contracts with hospitals and hospital systems at that price.
What could go wrong? The NCD process does not guarantee national coverage. If CMS ultimately declines to extend Medicare reimbursement nationally, adoption could slow significantly — particularly among the 65-and-over population that makes up Medicare's core beneficiary base. EBR also needs shareholder approval for the second $35 million tranche of its placement, with a vote expected in August.
The steep discount on the raise — nearly 20% — signals dilution risk for existing shareholders who don't participate.
The signal: Brandon Capital Partners, an investment fund that committed up to $46.65 million to this raise, is doubling down on a late-growth medtech at the precise inflection point between regulatory clearance and commercial scale — a bet that the hardest part is now behind EBR. For ASX-listed medtechs eyeing the US market, the emerging playbook is clear: secure FDA breakthrough designation, lock in reimbursement via fast-tracked Medicare pathways, then raise big to fund a rapid rollout before the coverage window narrows.
Read more: stockhead.com.au
